-
1
-
-
0028061499
-
Multiple serotonin receptors: Clinical and experimental aspects
-
Roth B.L. Multiple serotonin receptors: Clinical and experimental aspects. Ann. Clin. Psychiatry 6 (1994) 67-78
-
(1994)
Ann. Clin. Psychiatry
, vol.6
, pp. 67-78
-
-
Roth, B.L.1
-
2
-
-
0002254593
-
Atypical antipsychotic drugs: Clinical and preclinical features
-
J. Csernansky, ed, in press
-
Fatemi, S. H., Meltzer, H. Y., and Roth, B. L. Atypical antipsychotic drugs: Clinical and preclinical features. In Handbook of Experimental Pharmacology. (J. Csernansky, ed.) (in press).
-
Handbook of Experimental Pharmacology
-
-
Fatemi, S.H.1
Meltzer, H.Y.2
Roth, B.L.3
-
3
-
-
0026638381
-
Binding of typical and atypical antipsychotic drugs to transiently expressed 5-HT1c receptors
-
Roth B.L., Ciaranello R.D., and Meltzer H.Y. Binding of typical and atypical antipsychotic drugs to transiently expressed 5-HT1c receptors. J. Pharmacol. Exp. Ther 260 (1992) 1361-1366
-
(1992)
J. Pharmacol. Exp. Ther
, vol.260
, pp. 1361-1366
-
-
Roth, B.L.1
Ciaranello, R.D.2
Meltzer, H.Y.3
-
4
-
-
0028261434
-
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine (5-HT6) and 5-hydroxytryptamine7 (5-HT7) receptors
-
Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma Jr. F.J., Shen Y., Meltzer H.Y., and Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine (5-HT6) and 5-hydroxytryptamine7 (5-HT7) receptors. J. Pharmacol. Exp. Ther 268 (1994) 1403-1410
-
(1994)
J. Pharmacol. Exp. Ther
, vol.268
, pp. 1403-1410
-
-
Roth, B.L.1
Craigo, S.C.2
Choudhary, M.S.3
Uluer, A.4
Monsma Jr., F.J.5
Shen, Y.6
Meltzer, H.Y.7
Sibley, D.R.8
-
5
-
-
0028990758
-
D4 dopamine receptor affinity does not distinguish between typical and atypical antipsychotic drugs
-
Roth B.L., Khan N., Sibley D.R., and Meltzer H.Y. D4 dopamine receptor affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120 (1995) 265-368
-
(1995)
Psychopharmacology
, vol.120
, pp. 265-368
-
-
Roth, B.L.1
Khan, N.2
Sibley, D.R.3
Meltzer, H.Y.4
-
6
-
-
0028875303
-
Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
-
Seeger T.G., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., McLean S., Guanowsky V., Howard H.R., Lowe J.A., and Heym J. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther 225 (1995) 101-113
-
(1995)
J. Pharmacol. Exp. Ther
, vol.225
, pp. 101-113
-
-
Seeger, T.G.1
Seymour, P.A.2
Schmidt, A.W.3
Zorn, S.H.4
Schulz, D.W.5
Lebel, L.A.6
McLean, S.7
Guanowsky, V.8
Howard, H.R.9
Lowe, J.A.10
Heym, J.11
-
7
-
-
0026559370
-
Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists with a series of 3-substituted 1-(4-fluoropheny1)-1H-indoles
-
Perregaard J., Arnt J., Bogeso P., Hyttel J., and Sanchez C. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists with a series of 3-substituted 1-(4-fluoropheny1)-1H-indoles. J. Med. Chem 35 (1992) 1092-1101
-
(1992)
J. Med. Chem
, vol.35
, pp. 1092-1101
-
-
Perregaard, J.1
Arnt, J.2
Bogeso, P.3
Hyttel, J.4
Sanchez, C.5
|